A high-dose statin therapy for a post-acute coronary syndrome patient appears to produce no higher risk of kidney injury than a low-dose regimen. Study findings may reassure clinicians that high-potency statins are safe for patients after ACS. MedPage Today reports:
For post-acute coronary syndrome patients, high-dose statin therapy appeared to produce no higher a risk of kidney injury than a low-dose regimen, according to preliminary subanalyses of two randomized trials.
There were no differences between patients taking either 40 or 80 mg of a statin in creatinine elevations of >1.5, >2.0, and >3.0 mg/dL in the PROVE IT-TIMI 22 randomized trial, according to Amy Sarma, MD, MHS, of Brigham and Women's Hospital in Boston, and colleagues.
Similarly, in the A-to-Z Trial, researchers found no statistical differences in creatinine elevation at the same three increased levels between patients receiving 20 mg or 40 mg of statin therapy, Sarma reported during the American Heart Association's Emerging Science Series webinar.
Read the full story here: http://bit.ly/12ep1os
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Similar In-Hospital, Long-Term Survival Rates Found Among Male, Female Patients With AECOPD
March 18th 2024This study analyzed sex differences among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), with findings indicating that female smokers experience worse hospital outcomes despite similar overall survival rates.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
AstraZeneca joins efforts to address high drug prices by capping out-of-pocket costs for its inhalers; Opill, the first OTC birth control pill, is now accessible through online sales; expansion prompts questions on the effectiveness and regulation of remote monitoring technology.
Read More